Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||PF-06647263||Phase I||Actionable||In a Phase I trial, PF-06647263 treatment resulted in partial response in 2 patients with triple-receptor negative breast cancer (TNBC) in the solid tumor dose escalation cohort, but no objective response (0/10) in the TNBC dose expansion cohort (J Clin Oncol 35, 2017 (suppl; abstr 2511)).||detail...|
|PubMed Id||Reference Title||Details|
|A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer.||Full reference...|